Project Grant FF210K031004

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $601,340 to Transchromix LLC to develop a novel therapeutic intervention for early-stage type 1 diabetes (T1D). The research aims to target a translational regulatory mechanism involving the G9A histone methyltransferase, which was found to specifically suppress the pathogenicity of...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Chapman University will support the development of small molecule selective inhibitors of neuronal nitric oxide synthase (nNOS) for the treatment of melanoma. The key products and services to be delivered under this $610,415 award, which runs from Jun 2025 to May 2030, include: Designing and synthesizing novel nNOS inhibitors with improved potency, selectivity, and pharmacological properties....

The National Cancer Institute (NCI) awarded a $1,948,592 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Washington University to conduct a Phase 1 clinical trial assessing the safety, tolerability, pharmacokinetics, and anti-tumor activity of the novel ACK1 inhibitor (R)-9B in patients with castration-resistant prostate cancer (CRPC). The grant period runs from August 15, 2024 to July 31, 2029. The study aims to evaluate (R)-9B's ability to overcome CRPC resistance...

This Cooperative Agreement awarded by the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support the development of novel angiotensin AT2 receptor inhibitors for the treatment of neuropathic pain. The $818,360 award to the University of Southern California will fund research to optimize lead compounds showing improved potency, efficacy, and safety profiles compared...

This Project Grant award from the National Center for Complementary and Integrative Health (NCCIH), under the federal grant program "Research and Training in Complementary and Integrative Health" (CFDA 93.213), provides $242,310 to the University of Illinois to investigate alkaloid compounds from the Aristotelia plant as potential subtype-selective antagonists of nicotinic acetylcholine receptors (nAChRs). The research aims to extract and isolate known and novel Aristotelia...

This $310,897 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop a first-in-class, islet-targeted antibody therapeutic for Type 1 Diabetes (T1D). The award supports preclinical development and validation activities for this novel antibody therapy, including establishing proof-of-principle for its islet-homing capability, therapeutic...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $186,000.00 to The Institute For Cancer Research (ICR) to conduct pilot studies on a new tumor-targeted Aurora-A kinase (AURKA) inhibitor, NN-01-195. The goal is to establish the mechanism of action for NN-01-195 and evaluate its in vivo tumor accumulation and efficacy, benchmarking it against two parental compounds - the AURKA inhibitor TAS-119 and the HSP90 inhibitor SNX-2112. The...

This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Treatment Research Grant Program (CFDA 93.395), is providing $572,254 over a 3-year period starting February 1, 2025 to identify the first selective inhibitors of PLC𝜸1 and PLC𝜸2. The research aims to screen 200,000 compounds to discover small molecule inhibitors of these two phospholipase C gamma enzymes, which have been implicated in driving oncogenesis. The project will employ high-throughput screening...

This $298,045 Project Grant award from the National Institutes of Health's National Center for Advancing Translational Sciences (CFDA 93.350) aims to establish and develop a high-throughput screening (HTS) assay to identify novel bacterial DNA gyrase poisoning inhibitors. The key products and services to be delivered under this one-year award include: Developing a unique HTS assay to rapidly discover bacterial DNA gyrase poisoning inhibitors from small molecule libraries. This assay will...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to Cyrus Biotechnology, Inc., a minority-owned small disadvantaged business located in Seattle, WA. The funding supports research to develop an engineered immunoglobulin G (IgG) protease enzyme for the treatment of immune thrombocytopenia (ITP) and other IgG-mediated autoimmune diseases. The key objectives are...